Drug Profile
Isunakinra - Sesen Bio
Alternative Names: EBI 005 1; EBI 005 2; EBI-005Latest Information Update: 06 Jul 2023
Price :
$50
*
At a glance
- Originator Eleven Biotherapeutics
- Developer Buzzard Pharmaceuticals; Eleven Biotherapeutics
- Class Anti-inflammatories; Eye disorder therapies; Immunotherapies; Peptides; Proteins; Recombinant proteins
- Mechanism of Action Interleukin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Discontinued Allergic conjunctivitis; Dry eyes
Most Recent Events
- 02 Jun 2023 Interim pharmacokinetics, adverse events and efficacy data from a phase-I/II trial in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023) (NCT04121442)
- 29 Dec 2022 Isunakinra is still in phase I/IIs trial for solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (unspecified route) (NCT04121442)
- 29 Dec 2022 Isunakinra is still in phase I/IIs trial for solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable, Combination therapy) in USA (unspecified route) (NCT04121442)